This requires careful consideration of the administration of JAK inhibitors (or TYK2 inhibitors) in the context of inhibiting IL-6-mediated inflammatory responses, as the IFN-I responses are not supposed to be suppressed due to their positive roles in early infection. The gene discussed is IL6; the disease is infection.